Could a higher dose of reblozyl free MDS patients from frequent transfusions?

NCT ID NCT06045689

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether starting luspatercept (Reblozyl) at the maximum approved dose can help people with low-risk myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 participants who currently need regular transfusions will receive the drug. The main goal is to see if they can maintain higher hemoglobin levels without transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept (Reblozyl)
What this could lead to: If successful, this could help people with low-risk MDS need fewer blood transfusions and maintain higher hemoglobin levels.
What could go wrong: This is an early-stage Phase 3 trial with only 106 participants. Results may not apply to all MDS patients, and side effects from luspatercept are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Local Institution - 0001

Poitiers, Vienne, 86021, France
Local Institution - 0003

Milwaukee, Wisconsin, 53226, United States
Local Institution - 0004

Prague, Praha, Hlavní Mesto, 128 21, Czechia
Local Institution - 0005

Barcelona, 08035, Spain
Local Institution - 0007

Grenoble, 38 38043, France
Local Institution - 0008

Roeselare, West-Vlaanderen, 8800, Belgium
Local Institution - 0009

Leipzig, Saxony, 04103, Germany
Local Institution - 0010

Warsaw, Masovian Voivodeship, 02-172, Poland
Local Institution - 0011

Detroit, Michigan, 48202, United States
Local Institution - 0013

München, Bavaria, 81675, Germany
Local Institution - 0014

Novara, Piedmont, 28100, Italy
Local Institution - 0015

Pavia, Lombardy, 27100, Italy
Local Institution - 0016

Leuven, Vlaams Brabant, 3000, Belgium
Local Institution - 0017

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Local Institution - 0018

Valencia, 46010, Spain
Local Institution - 0020

Kansas City, Kansas, 66160-8500, United States
Local Institution - 0021

Reggio Calabria, Calabria, 89124, Italy
Local Institution - 0022

Huntsville, Texas, 77340-4101, United States
Local Institution - 0023

Prague, Praha, Hlavní Mesto, 128 20, Czechia
Local Institution - 0024

Florence, Tuscany, 50139, Italy
Local Institution - 0025

Paducah, Kentucky, 42003-7915, United States
Local Institution - 0026

Angers, 49933, France
Local Institution - 0027

Ourense, 32005, Spain
Local Institution - 0028

Salamanca, 37007, Spain
Local Institution - 0029

Rozzano (MI), Milano, 20089, Italy
Local Institution - 0031

Wheeling, West Virginia, 26003, United States
Local Institution - 0032

New York, New York, 10029, United States
Local Institution - 0033

New Haven, Connecticut, 06510, United States
Local Institution - 0034

Katowice, 40-519, Poland
Local Institution - 0035

Wałbrzych, 58-309, Poland
Local Institution - 0036

Pittsburgh, Pennsylvania, 15224, United States
Local Institution - 0038

Madrid, 28006, Spain
Local Institution - 0039

Granada, 18014, Spain
Local Institution - 0040

Hanover, Lower Saxony, 30161, Germany
Local Institution - 0041

Nice, Alpes-Maritimes, 06202, France
Local Institution - 0043

Amarillo, Texas, 79106-1781, United States
Local Institution - 0044

Tour Cedex01, 37044, France
Local Institution - 0045

Turin, Piedmont, 10128, Italy
Local Institution - 0046

Paris, 75475, France
Local Institution - 0047

San Juan, 00917, Puerto Rico
Local Institution - 0049

Lódz, Lódzkie, 93-513, Poland
Local Institution - 0050

Rome, Lazio, 00133, Italy
Local Institution - 0051

Los Alamitos, California, 90720-3309, United States
Local Institution - 0052

Barcelona, 08916, Spain
Local Institution - 0053

Pierre-Bénite, 69495, France
Local Institution - 0054

Eugene, Oregon, 97401-6043, United States
Local Institution - 0055

St. Petersburg, Florida, 33705, United States
Local Institution - 0056

Wellington, Florida, 33414, United States
Local Institution - 0058

Morristown, New Jersey, 07960-6136, United States
Local Institution - 0059

St Louis, Missouri, 63110, United States
Local Institution - 0062

Naples, Campania, 80131, Italy
Local Institution - 0063

Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.